Early detection of toxicity and adjustment of ongoing clinical trials: The history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program

Journal of Clinical Oncology

Volumn 20, Issue 23, 2002, Pages 4591-4596

  Goldberg, Richard M ^a   Sargent, Daniel J ^a   Morton, Roscoe F ^a   Mahoney, Michelle R ^a   Krook, James E ^a   O'Connell, Michael J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MONITORING; HUMAN; PATIENT CARE; PRIORITY JOURNAL; TOXICITY TESTING; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; EVIDENCE-BASED MEDICINE; HUMANS; MULTICENTER STUDIES; PROSPECTIVE STUDIES; UNITED STATES;

EID: 0036895122     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.03.039     Document Type: Article

References (11)

1. Ellenberg S, Geller N, Simon R, et al (eds): Practical issues in data monitoring of clinical trials. Stat Med 12:414-616, 1993
2. Sargent DJ, Goldberg RM, Mahoney MR, et al: Rapid reporting and review of an increased incidence of a known adverse event. J Natl Cancer Inst 92:1011-1013, 2000
3. Fonseca R, Goldberg RM, Erlichman C, et al: Phase I study of CPT-11/5-FU/leucovorin. Proc Am Assoc Cancer Res 38:76, 1997 (abstr)
4. Wasserman E, Goldwasser F, Ouldkaci M, et al: CPT-11/oxaliplatin (L-OHP) every 3 weeks: An active combination in colorectal cancer (CRC). Proc Am Assoc Cancer Res 39:A2190, 1998 (abstr)
5. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000
6. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18:2938-2947, 2000
7. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355: 1041-1047, 2000
8. Goldberg RM, Hatfield AK, Kahn M, et al: A prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the 1-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol 15:3320-3329, 1997
9. Leichman CG, Fleming TR, Franco MM, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13:1303-1311, 1995
10. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001
11. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144-145, 2001